Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response.

Sharon D, Cathelin S, Mirali S, Di Trani JM, Yanofsky DJ, Keon KA, Rubinstein JL, Schimmer AD, Ketela T, Chan SM.

Sci Transl Med. 2019 Oct 30;11(516). pii: eaax2863. doi: 10.1126/scitranslmed.aax2863.

PMID:
31666400
2.

Evaluation of methods to assign cell type labels to cell clusters from single-cell RNA-sequencing data.

Diaz-Mejia JJ, Meng EC, Pico AR, MacParland SA, Ketela T, Pugh TJ, Bader GD, Morris JH.

Version 3. F1000Res. 2019 Mar 15 [revised 2019 Jan 1];8. pii: ISCB Comm J-296. doi: 10.12688/f1000research.18490.3. eCollection 2019.

3.

Forward genetic screen in human podocytes identifies diphthamide biosynthesis genes as regulators of adhesion.

Cinà DP, Ketela T, Brown KR, Chandrashekhar M, Mero P, Li C, Onay T, Fu Y, Han Z, Saleem M, Moffat J, Quaggin SE.

Am J Physiol Renal Physiol. 2019 Dec 1;317(6):F1593-F1604. doi: 10.1152/ajprenal.00195.2019. Epub 2019 Sep 30.

PMID:
31566424
4.

The Mitochondrial Transacylase, Tafazzin, Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids.

Seneviratne AK, Xu M, Aristizabal Henao JJ, Fajardo VA, Hao Z, Voisin V, Xu GW, Hurren R, Kim S, MacLean N, Wang X, Gronda M, Jeyaraju D, Jitkova Y, Ketela T, Mullokandov M, Sharon D, Thomas G, Chouinard-Watkins R, Hawley JR, Schafer C, Yau HL, Khuchua Z, Aman A, Al-Awar R, Gross A, Claypool SM, Bazinet RP, Lupien M, Chan S, De Carvalho DD, Minden MD, Bader GD, Stark KD, LeBlanc P, Schimmer AD.

Cell Stem Cell. 2019 Jun 6;24(6):1007. doi: 10.1016/j.stem.2019.04.020. No abstract available.

PMID:
31173706
5.

Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide.

Hunter FW, Devaux JBL, Meng F, Hong CR, Khan A, Tsai P, Ketela TW, Sharma I, Kakadia PM, Marastoni S, Shalev Z, Hickey AJR, Print CG, Bohlander SK, Hart CP, Wouters BG, Wilson WR.

Mol Pharmacol. 2019 Jun;95(6):638-651. doi: 10.1124/mol.118.115196. Epub 2019 Apr 12.

PMID:
30979813
6.

The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids.

Seneviratne AK, Xu M, Henao JJA, Fajardo VA, Hao Z, Voisin V, Xu GW, Hurren R, Kim S, MacLean N, Wang X, Gronda M, Jeyaraju D, Jitkova Y, Ketela T, Mullokandov M, Sharon D, Thomas G, Chouinard-Watkins R, Hawley JR, Schafer C, Yau HL, Khuchua Z, Aman A, Al-Awar R, Gross A, Claypool SM, Bazinet RP, Lupien M, Chan S, De Carvalho DD, Minden MD, Bader GD, Stark KD, LeBlanc P, Schimmer AD.

Cell Stem Cell. 2019 Apr 4;24(4):621-636.e16. doi: 10.1016/j.stem.2019.02.020. Epub 2019 Mar 28. Erratum in: Cell Stem Cell. 2019 Jun 6;24(6):1007.

PMID:
30930145
7.

The Inhibitory NKR-P1B:Clr-b Recognition Axis Facilitates Detection of Oncogenic Transformation and Cancer Immunosurveillance.

Tanaka M, Fine JH, Kirkham CL, Aguilar OA, Belcheva A, Martin A, Ketela T, Moffat J, Allan DSJ, Carlyle JR.

Cancer Res. 2018 Jul 1;78(13):3589-3603. doi: 10.1158/0008-5472.CAN-17-1688. Epub 2018 Apr 24.

8.

Developmental Emergence of Adult Neural Stem Cells as Revealed by Single-Cell Transcriptional Profiling.

Yuzwa SA, Borrett MJ, Innes BT, Voronova A, Ketela T, Kaplan DR, Bader GD, Miller FD.

Cell Rep. 2017 Dec 26;21(13):3970-3986. doi: 10.1016/j.celrep.2017.12.017.

9.

The Candida albicans transcription factor Cas5 couples stress responses, drug resistance and cell cycle regulation.

Xie JL, Qin L, Miao Z, Grys BT, Diaz JC, Ting K, Krieger JR, Tong J, Tan K, Leach MD, Ketela T, Moran MF, Krysan DJ, Boone C, Andrews BJ, Selmecki A, Ho Wong K, Robbins N, Cowen LE.

Nat Commun. 2017 Sep 11;8(1):499. doi: 10.1038/s41467-017-00547-y.

10.

SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress.

Zipin-Roitman A, Aqaqe N, Yassin M, Biechonski S, Amar M, van Delft MF, Gan OI, McDermott SP, Buzina A, Ketela T, Shlush L, Xie S, Voisin V, Moffat J, Minden MD, Dick JE, Milyavsky M.

Oncotarget. 2017 Mar 7;8(10):16712-16727. doi: 10.18632/oncotarget.15147.

11.

Functional Genomic Analysis of Candida albicans Adherence Reveals a Key Role for the Arp2/3 Complex in Cell Wall Remodelling and Biofilm Formation.

Lee JA, Robbins N, Xie JL, Ketela T, Cowen LE.

PLoS Genet. 2016 Nov 21;12(11):e1006452. doi: 10.1371/journal.pgen.1006452. eCollection 2016 Nov.

12.

The SAGA Deubiquitination Module Promotes DNA Repair and Class Switch Recombination through ATM and DNAPK-Mediated γH2AX Formation.

Ramachandran S, Haddad D, Li C, Le MX, Ling AK, So CC, Nepal RM, Gommerman JL, Yu K, Ketela T, Moffat J, Martin A.

Cell Rep. 2016 May 17;15(7):1554-1565. doi: 10.1016/j.celrep.2016.04.041. Epub 2016 May 5.

13.

Cytokinetic effects of Wee1 disruption in pancreatic cancer.

Chang Q, Chandrashekhar M, Ketela T, Fedyshyn Y, Moffat J, Hedley D.

Cell Cycle. 2016;15(4):593-604. doi: 10.1080/15384101.2016.1138188.

14.

Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.

Hunter FW, Young RJ, Shalev Z, Vellanki RN, Wang J, Gu Y, Joshi N, Sreebhavan S, Weinreb I, Goldstein DP, Moffat J, Ketela T, Brown KR, Koritzinsky M, Solomon B, Rischin D, Wilson WR, Wouters BG.

Cancer Res. 2015 Oct 1;75(19):4211-23. doi: 10.1158/0008-5472.CAN-15-1107. Epub 2015 Aug 21.

15.

Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.

Workenhe ST, Ketela T, Moffat J, Cuddington BP, Mossman KL.

Oncogene. 2016 May 12;35(19):2465-74. doi: 10.1038/onc.2015.303. Epub 2015 Aug 10.

PMID:
26257065
16.

Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia.

Cole A, Wang Z, Coyaud E, Voisin V, Gronda M, Jitkova Y, Mattson R, Hurren R, Babovic S, Maclean N, Restall I, Wang X, Jeyaraju DV, Sukhai MA, Prabha S, Bashir S, Ramakrishnan A, Leung E, Qia YH, Zhang N, Combes KR, Ketela T, Lin F, Houry WA, Aman A, Al-Awar R, Zheng W, Wienholds E, Xu CJ, Dick J, Wang JC, Moffat J, Minden MD, Eaves CJ, Bader GD, Hao Z, Kornblau SM, Raught B, Schimmer AD.

Cancer Cell. 2015 Jun 8;27(6):864-76. doi: 10.1016/j.ccell.2015.05.004.

17.

Global analysis of fungal morphology exposes mechanisms of host cell escape.

O'Meara TR, Veri AO, Ketela T, Jiang B, Roemer T, Cowen LE.

Nat Commun. 2015 Mar 31;6:6741. doi: 10.1038/ncomms7741.

18.

Differential regulation of FGFR3 by PTPN1 and PTPN2.

St-Germain JR, Taylor P, Zhang W, Li Z, Ketela T, Moffat J, Neel BG, Trudel S, Moran MF.

Proteomics. 2015 Jan;15(2-3):419-33. doi: 10.1002/pmic.201400259. Epub 2014 Dec 17.

19.

The RhoGEF GEF-H1 is required for oncogenic RAS signaling via KSR-1.

Cullis J, Meiri D, Sandi MJ, Radulovich N, Kent OA, Medrano M, Mokady D, Normand J, Larose J, Marcotte R, Marshall CB, Ikura M, Ketela T, Moffat J, Neel BG, Gingras AC, Tsao MS, Rottapel R.

Cancer Cell. 2014 Feb 10;25(2):181-95. doi: 10.1016/j.ccr.2014.01.025.

20.

shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer.

Deng T, Liu JC, Chung PE, Uehling D, Aman A, Joseph B, Ketela T, Jiang Z, Schachter NF, Rottapel R, Egan SE, Al-Awar R, Moffat J, Zacksenhaus E.

Cancer Res. 2014 Apr 1;74(7):2119-30. doi: 10.1158/0008-5472.CAN-13-2138. Epub 2014 Jan 31.

21.

A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities.

Vizeacoumar FJ, Arnold R, Vizeacoumar FS, Chandrashekhar M, Buzina A, Young JT, Kwan JH, Sayad A, Mero P, Lawo S, Tanaka H, Brown KR, Baryshnikova A, Mak AB, Fedyshyn Y, Wang Y, Brito GC, Kasimer D, Makhnevych T, Ketela T, Datti A, Babu M, Emili A, Pelletier L, Wrana J, Wainberg Z, Kim PM, Rottapel R, O'Brien CA, Andrews B, Boone C, Moffat J.

Mol Syst Biol. 2013 Oct 8;9:696. doi: 10.1038/msb.2013.54.

22.

Interaction domains of Sos1/Grb2 are finely tuned for cooperative control of embryonic stem cell fate.

Findlay GM, Smith MJ, Lanner F, Hsiung MS, Gish GD, Petsalaki E, Cockburn K, Kaneko T, Huang H, Bagshaw RD, Ketela T, Tucholska M, Taylor L, Bowtell DD, Moffat J, Ikura M, Li SS, Sidhu SS, Rossant J, Pawson T.

Cell. 2013 Feb 28;152(5):1008-20. doi: 10.1016/j.cell.2013.01.056.

23.

Suppression of cancer progression by MGAT1 shRNA knockdown.

Beheshti Zavareh R, Sukhai MA, Hurren R, Gronda M, Wang X, Simpson CD, Maclean N, Zih F, Ketela T, Swallow CJ, Moffat J, Rose DR, Schachter H, Schimmer AD, Dennis JW.

PLoS One. 2012;7(9):e43721. doi: 10.1371/journal.pone.0043721. Epub 2012 Sep 5.

24.

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, Krzyzanowski PM, Sircoulomb F, Medrano M, Fedyshyn Y, Koh JLY, van Dyk D, Fedyshyn B, Luhova M, Brito GC, Vizeacoumar FJ, Vizeacoumar FS, Datti A, Kasimer D, Buzina A, Mero P, Misquitta C, Normand J, Haider M, Ketela T, Wrana JL, Rottapel R, Neel BG, Moffat J.

Cancer Discov. 2012 Feb;2(2):172-189. doi: 10.1158/2159-8290.CD-11-0224. Epub 2011 Dec 29.

25.

A genome wide shRNA screen identifies α/β hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance.

Simpson CD, Hurren R, Kasimer D, MacLean N, Eberhard Y, Ketela T, Moffat J, Schimmer AD.

Apoptosis. 2012 Jul;17(7):666-78. doi: 10.1007/s10495-012-0723-4.

PMID:
22488300
26.

Analysis of early C2C12 myogenesis identifies stably and differentially expressed transcriptional regulators whose knock-down inhibits myoblast differentiation.

Rajan S, Chu Pham Dang H, Djambazian H, Zuzan H, Fedyshyn Y, Ketela T, Moffat J, Hudson TJ, Sladek R.

Physiol Genomics. 2012 Feb 1;44(2):183-97. doi: 10.1152/physiolgenomics.00093.2011. Epub 2011 Dec 6.

PMID:
22147266
27.

COLT-Cancer: functional genetic screening resource for essential genes in human cancer cell lines.

Koh JL, Brown KR, Sayad A, Kasimer D, Ketela T, Moffat J.

Nucleic Acids Res. 2012 Jan;40(Database issue):D957-63. doi: 10.1093/nar/gkr959. Epub 2011 Nov 18.

28.

Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia.

Skrtić M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z, Hurren R, Jitkova Y, Gronda M, Maclean N, Lai CK, Eberhard Y, Bartoszko J, Spagnuolo P, Rutledge AC, Datti A, Ketela T, Moffat J, Robinson BH, Cameron JH, Wrana J, Eaves CJ, Minden MD, Wang JC, Dick JE, Humphries K, Nislow C, Giaever G, Schimmer AD.

Cancer Cell. 2011 Nov 15;20(5):674-88. doi: 10.1016/j.ccr.2011.10.015.

29.

CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope.

Mak AB, Blakely KM, Williams RA, Penttilä PA, Shukalyuk AI, Osman KT, Kasimer D, Ketela T, Moffat J.

J Biol Chem. 2011 Nov 25;286(47):41046-56. doi: 10.1074/jbc.M111.261545. Epub 2011 Sep 21.

30.

Pooled lentiviral shRNA screening for functional genomics in mammalian cells.

Blakely K, Ketela T, Moffat J.

Methods Mol Biol. 2011;781:161-82. doi: 10.1007/978-1-61779-276-2_9.

PMID:
21877282
31.

A comprehensive platform for highly multiplexed mammalian functional genetic screens.

Ketela T, Heisler LE, Brown KR, Ammar R, Kasimer D, Surendra A, Ericson E, Blakely K, Karamboulas D, Smith AM, Durbic T, Arnoldo A, Cheung-Ong K, Koh JL, Gopal S, Cowley GS, Yang X, Grenier JK, Giaever G, Root DE, Moffat J, Nislow C.

BMC Genomics. 2011 May 6;12:213. doi: 10.1186/1471-2164-12-213.

32.

Inhibition of SREBP1 sensitizes cells to death ligands.

Eberhard Y, Gronda M, Hurren R, Datti A, MacLean N, Ketela T, Moffat J, Wrana JL, Schimmer AD.

Oncotarget. 2011 Mar;2(3):186-96.

33.

SATB2 augments ΔNp63α in head and neck squamous cell carcinoma.

Chung J, Lau J, Cheng LS, Grant RI, Robinson F, Ketela T, Reis PP, Roche O, Kamel-Reid S, Moffat J, Ohh M, Perez-Ordonez B, Kaplan DR, Irwin MS.

EMBO Rep. 2010 Oct;11(10):777-83. doi: 10.1038/embor.2010.125. Epub 2010 Sep 10.

34.

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma.

Xu GW, Ali M, Wood TE, Wong D, Maclean N, Wang X, Gronda M, Skrtic M, Li X, Hurren R, Mao X, Venkatesan M, Beheshti Zavareh R, Ketela T, Reed JC, Rose D, Moffat J, Batey RA, Dhe-Paganon S, Schimmer AD.

Blood. 2010 Mar 18;115(11):2251-9. doi: 10.1182/blood-2009-07-231191. Epub 2010 Jan 14.

35.

Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands.

Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K, Mao X, Suarez Saiz F, Gronda M, Eberhard Y, MacLean N, Ketela T, Reed JC, Moffat J, Minden MD, Batey RA, Schimmer AD.

Mol Cancer Ther. 2010 Jan;9(1):246-56. doi: 10.1158/1535-7163.MCT-09-0495. Epub 2010 Jan 6.

36.

Systematic validation and atomic force microscopy of non-covalent short oligonucleotide barcode microarrays.

Cook MA, Chan CK, Jorgensen P, Ketela T, So D, Tyers M, Ho CY.

PLoS One. 2008 Feb 6;3(2):e1546. doi: 10.1371/journal.pone.0001546.

37.

Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans.

Xu D, Jiang B, Ketela T, Lemieux S, Veillette K, Martel N, Davison J, Sillaots S, Trosok S, Bachewich C, Bussey H, Youngman P, Roemer T.

PLoS Pathog. 2007 Jun;3(6):e92.

38.

Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast.

Parsons AB, Lopez A, Givoni IE, Williams DE, Gray CA, Porter J, Chua G, Sopko R, Brost RL, Ho CH, Wang J, Ketela T, Brenner C, Brill JA, Fernandez GE, Lorenz TC, Payne GS, Ishihara S, Ohya Y, Andrews B, Hughes TR, Frey BJ, Graham TR, Andersen RJ, Boone C.

Cell. 2006 Aug 11;126(3):611-25.

39.

Harvesting the genome's bounty: integrative genomics.

Jorgensen P, Breitkreutz BJ, Breitkreutz K, Stark C, Liu G, Cook M, Sharom J, Nishikawa JL, Ketela T, Bellows D, Breitkreutz A, Rupes I, Boucher L, Dewar D, Vo M, Angeli M, Reguly T, Tong A, Andrews B, Boone C, Tyers M.

Cold Spring Harb Symp Quant Biol. 2003;68:431-43. Review. No abstract available.

PMID:
15338646
40.

Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery.

Roemer T, Jiang B, Davison J, Ketela T, Veillette K, Breton A, Tandia F, Linteau A, Sillaots S, Marta C, Martel N, Veronneau S, Lemieux S, Kauffman S, Becker J, Storms R, Boone C, Bussey H.

Mol Microbiol. 2003 Oct;50(1):167-81.

41.

Comprehensive essential gene identification as a platform for novel anti-infective drug discovery.

Haselbeck R, Wall D, Jiang B, Ketela T, Zyskind J, Bussey H, Foulkes JG, Roemer T.

Curr Pharm Des. 2002;8(13):1155-72. Review.

PMID:
12052225
43.

Yeast Skn7p activity is modulated by the Sln1p-Ypd1p osmosensor and contributes to regulation of the HOG pathway.

Ketela T, Brown JL, Stewart RC, Bussey H.

Mol Gen Genet. 1998 Sep;259(4):372-8.

PMID:
9790591
44.

Unidentified antioxidant defences of human plasma in immobilized patients: a possible relation to basic metabolic rate.

Aejmelaeus R, Ketelä TM, Pirttilä T, Hervonen A, Alho H.

Free Radic Res. 1997 Apr;26(4):335-41.

PMID:
9167938
45.
46.

Genetic correlation of the orf224/atp6 gene region with Polima CMS in Brassica somatic hybrids.

Wang HM, Ketela T, Keller WA, Gleddie SC, Brown GG.

Plant Mol Biol. 1995 Feb;27(4):801-7.

PMID:
7727756
47.

RNA editing of transcripts of a chimeric mitochondrial gene associated with cytoplasmic male-sterility in Brassica.

Stahl R, Sun S, L'Homme Y, Ketela T, Brown GG.

Nucleic Acids Res. 1994 Jun 11;22(11):2109-13.

Supplemental Content

Loading ...
Support Center